MO1-19-3 Final analysis of survival outcomes in the KSCC1501A trial of up-front therapy for HER2-negative advanced gastric cancer.

MLA

Makiyama, Akitaka, et al. “MO1-19-3 Final Analysis of Survival Outcomes in the KSCC1501A Trial of up-Front Therapy for HER2-Negative Advanced Gastric Cancer.” Annals of Oncology, vol. 30, Oct. 2019, p. N.PAG. EBSCOhost, https://doi.org/10.1093/annonc/mdz338.036.

APA

Makiyama, A., Shinozaki, K., Kashiwada, T., Kawanaka, H., Tanioka, H., Okita, Y., Fukahori, M., Hayashi, N., Shimokawa, M., Saeki, H., Oki, E., Baba, E., Baba, H., & Mori, M. (2019). MO1-19-3 Final analysis of survival outcomes in the KSCC1501A trial of up-front therapy for HER2-negative advanced gastric cancer. Annals of Oncology, 30, N.PAG. https://doi.org/10.1093/annonc/mdz338.036

Chicago

Makiyama, Akitaka, Katsunori Shinozaki, Tomomi Kashiwada, Hirofumi Kawanaka, Hiroaki Tanioka, Yoshihiro Okita, Masaru Fukahori, et al. 2019. “MO1-19-3 Final Analysis of Survival Outcomes in the KSCC1501A Trial of up-Front Therapy for HER2-Negative Advanced Gastric Cancer.” Annals of Oncology 30 (October): N.PAG. doi:10.1093/annonc/mdz338.036.